Ranbaxy Enhances Facility Operations But Deadlock On FDA Action Remains
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Daiichi Sankyo's India affiliate Ranbaxy has put in place enhanced systems and processes to upgrade its manufacturing facilities and R&D centers to respond to U.S. FDA punitive actions related to alleged lapses in good manufacturing practices at Ranbaxy's two India-based sites